Obesity modulation - the role in carcinogenesis

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 6, 2010, Pages 481-490

  Legakis, Ioannis ^a   Syrigos, Kostantinos ^b  

^a HENRY DUNANT HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adiponectin; Carcinogenesis; Ghrelin; Insulin like growth factors; Leptin; Metabolic syndrome

Indexed keywords

ADIPONECTIN; FATTY ACID; GHRELIN; INSULIN; LEPTIN; SOMATOMEDIN;

ADIPOCYTE; ANOREXIA; ARTICLE; BODY WEIGHT; BREAST CANCER; CACHEXIA; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INTERACTION; CLINICAL STUDY; DIGESTIVE SYSTEM CANCER; EUROPE; HUMAN; INCIDENCE; INSULIN RESISTANCE; MEDICAL RESEARCH; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PREVALENCE; PROSTATE CANCER; TUMOR GROWTH; UNITED STATES;

EID: 78649866367     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009060481     Document Type: Article

References (185)

1. Straus, D.S. Growth-stimulatory actions of insulin in vitro and invivo. Endocr. Rev., 1984, 5, 356-69.
2. Cleland, S.J.; Petrie, J.R.; Ueda, S.; Elliott, H.L.; Connell, J.M.Insulin as a vascular hormone: implications for the pathophysiologyof cardiovascular disease. Clin. Exp. Pharmacol. Physiol., 1998, 25 (3-4), 175-184.
3. Berg, A.H.; Scherer, P.E. Adipose tissue, inflammation, and cardiovasculardisease. Circ. Res., 2005, 96(9), 939-949.
4. Keaney, J.F. Jr.; Larson, M.G.; Vasan, R.S.; Wilson, P.W.; Lipinska, I.; Corey, D.; Massaro, J.M.; Sutherland, P.; Vita, JA, Benjamin, EJ; Framingham Study. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler.Thromb. Vasc. Biol., 2003, 23(3), 434 -439.
5. Tschop, M.; Weyer, C.; Tataranni, P.A; Devanarayan, V.; Ravussin, E.; Heiman, L.M. Circulating ghrelin levels are decreased in humanobesity. Diabetes, 2001, 50(4), 707-709.
6. Reaven, G.M. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu. Rev. Nutr., 2005, 25, 391-406.
7. Halford, J.C. Clinical pharmacotherapy for obesity: current drugsand those in advanced development. Curr. Drug Targets, 2004, 5(7), 637-646.
8. Hamman, R.F.; Wing, R, R.; Edelstein, S.L.; Lachin, J.M.; Bray, G.A.; Delahanty, L.; Hoskin, M.; Kriska, A.M.; Mayer-Davis, E.J.; Pi-Sunyer, X.; Regensteiner, J.; Venditti, B. Wylie-Rosett, J. Effectof weight loss with lifestyle intervention on risk of diabetes. DiabetesCare, 2006, 29(9), 2102-2107.
9. Rissanen, A. Pharmacological intervention: the antiobesity approach.Eur. J. Clin. Invest., 1998, 28(suppl 2), 27-30.
10. Ronti, T.; Lupattelli, G.; Mannarino, E. The endocrine function of adipose tissue: an update. Clin. Endocrinol. (Oxf), 2006, 64(4), 355-365.
11. Yoshii, H.;, Lam, T.K.; Gupta, N.; Goh, T.; Haber, C.A.; Uchino, H.; Kim, T.T.; Chong, V.Z.; Shah, K.; Fantus, I.G.; Mari, A.; Kawamori, R.; Giacca, A. Effects of portal free fatty acid elevation oninsulin clearance and hepatic glucose flux. Am. J. Physiol. Endocrinol.Metab., 2006, 290(6), E1089 -97.
12. Legaspi, A.; Jeevanandam, M.; Starnes, H.F. Jr.; Brennan, M.F.Whole body lipid and energy metabolism in the cancer patient.Metabolism, 1987, 36(10), 958-963.
13. Stulnig, T.M.; Berger, M.; Roden, M.; Stingl, H.; Raederstorff, D.; Waldhausl, W. Elevated serum free fatty acid concentrations inhibitT lymphocyte signaling. FASEB J., 2000, 14(7), 939-947.
14. Hardy, S.; St Onge, G.G.; Joly, E.; Langelier, Y.; Prentki, M.Oleate promotes the proliferation of breast cancer cells via theGprotein-coupled receptor GPR40. J. Biol. Chem., 2005, 280(14), 13285-13291.
15. Khandwala, H.M.; McCutcheon, I.E.; Flyvbjerg, A.; Friend, K.E.The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev., 2000, 21(3), 215-244.
16. Jones, J.I.; Clemmons, D.R. Insulin-like growth factors and theirbinding proteins: biological actions. Endocr. Rev., 1995, 16(1), 3-34.
17. Rajaram, S.; Baylink, D.J.; Mohan, S. Insulin-like growth factorbindingproteins in serum and other biological fluids: regulationand functions. Endocr. Rev., 1997, 18(6), 801-831.
18. Pollak, M. Insulin-like growth factor physiology and cancer risk.Eur. J. Cancer, 2000, 36(10), 1224-1228.
19. Chan, J.M.; Stampfer, M.J.; Giovannucci, E.; Gann, P.H.; Ma, J.; Wilkinson, P.; Hennekens, C.H.; Pollak, M. Plasma insulin-likegrowth factor-I and prostate cancer risk: a prospective study.Science, 1998, 279(5350), 563-566.
20. Hankinson, S.E.; Willett, W.C.; Colditz, G.A.; Hunter, D.J.; Michaud, D.S.; Deroo, B.; Rosner, B.; Speizer, F.E.; Pollak, M.Circulating concentrations of insulin-like growth factor-I and riskof breast cancer. Lancet, 1998, 351(9113), 1393-1396.
21. Ma, J.; Pollak, M.N.; Giovannucci, E.; Chan, J.M.; Tao, Y.; Hennekens, C.H.; Stampfer, M.J. Prospective study of colorectal cancerrisk in men and plasma levels of insulin-like growth factor (IGF)-Iand IGF-binding protein-3. J. Natl. Cancer Inst., 1999, 91(7), 620-625.
22. Yu, H.; Spitz, M.R.; Mistry, J.; Gu, J.; Hong, W.K.; Wu, X. Plasmalevels of insulin-like growth factor-I and lung cancer risk: a casecontrolanalysis. J. Natl. Cancer Inst., 1999, 91(2), 151-156.
23. Yu, H.; Rohan, T. Role of the insulin-like growth factor family incancer development and progression. J. Natl. Cancer Inst., 2000, 92(18), 1472-1489.
24. Giovannucci, E. Insulin, insulin-like growth factors and coloncancer: a review of the evidence. J. Nutr., 2001, 131 (suppl), S3109-20.
25. Firth, S.M.; Baxter, R.C. Cellular actions of the insulin-like growthfactor binding proteins. Endocr. Rev., 2002, 23(6), 824-854.
26. Stewart, B.W.; Kleihues, P. WHO/International Agency for Researchon Cancer, World Cancer Report. Lyon: IARC Press, 2003.
27. Platz, E.A.; Pollak, M.N.; Rimm, E.B.; Majeed, N.; Tao, Y.; Willett, W.C.; Giovannucci, E. Racial variation in insulin-likegrowth factor-1 and binding protein-3 concentrations in middleagedmen. Cancer Epidemiol. Biomarkers Prev., 1999, 8(12), 1107-1110.
28. Renehan, A.G.; Jones, J.; O'Dwyer, S.T.; Shalet, S.M. Determinationof IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: comparisons using the Bland-Altman method. GrowthHorm. IGF Res., 2003, 13(6), 341-346.
29. International Agency for Research on Cancer. Weight Control and Physical Activity. IARC handbooks of cancer prevention, (6) Lyon: IARC Press, 2002.
30. Thissen, J.P.; Ketelslegers, J.M.; Underwood, L.E. Nutritionalregulation of the insulin-like growth factors. Endocr. Rev., 1994, 15(1) 80-101.
31. Rosendal, L.;, Langberg, H.; Flyvbjerg, A.; Frystyk, J.; Ørskov, H.; Kjaer, M. Physical capacity influences the response of insulin-likegrowth factor and its binding proteins to training. J. Appl. Physiol., 2002, 93(5), 1669-1675.
32. Juul, A.; Bang, P.; Hertel, N.T.; Main, K.; Dalgaard, P.; Jørgensen, K.; Müller, J.; Hall, K.; Skakkebaek, N.E. Serum insulin-likegrowth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body massindex. J. Clin. Endocrinol. Metab., 1994, 78(3), 744-752.
33. Kaklamani, V.G.; Linos, A.; Kaklamani, E.; Markaki, I.; Mantzoros, C. Age, sex, and smoking are predictors of circulating insulinlikegrowth factor 1 and insulin-like growth factor-binding protein3. J. Clin. Oncol., 1999, 17(3), 813-817.
34. Wu, Y.; Yakar, S.; Zhao, L.; Hennighausen, L.; LeRoith, D. Circulatinginsulin-like growth factor-I levels regulate colon cancergrowth and metastasis. Cancer Res., 2002, 62(4), 1030-1035.
35. Frystyk, J.; Skjaerbaek, C.; Dinesen, B.; Orskov, H. Free insulinlikegrowth factors (IGF-I and IGF-II) in human serum. FEBS Lett., 1994, 348(2), 185-191.
36. Diamandi, A.; Mistry, J.; Krishna, R.G.; Khosravi, J. Immunoassayof insulin-like growth factor-binding protein-3 (IGFBP-3): newmeans to quantifying IGFBP-3 proteolysis. J. Clin. Endocrinol.Metab., 2000, 85(6), 2327-2333.
37. Kershaw, E.E.; Flier, J.S. Adipose tissue as an endocrine organ. J.Clin. Endocrinol. Metab., 2004, 89(6), 2548 -2556.
38. Maeda, K.; Okubo, K.; Shimomura, I.; Funahashi, T.; Matsuzawa, Y.; Matsubara, K. cDNA cloning and expression of a novel adiposespecific collagen-like factor, apM1 (AdiPose Most abundant Genetranscript 1). Biochem. Biophys. Res. Commun., 1996, 221(2), 286 -289.
39. Yokota, T.; Oritani, K.; Takahashi, I.; Ishikawa, J.; Matsuyama, A.; Ouchi, N.; Kihara, S.; Funahashi, T.; Tenner, A.J.; Tomiyama, Y.; Matsuzawa, Y. Adiponectin, a new member of the family of solubledefense collagens, negatively regulates the growth of myelomonocyticprogenitors and the functions of macrophages. Blood, 2000, 96(5), 1723-1732.
40. Arita, Y.; Kihara, S.; Ouchi, N.; Maeda, K.; Kuriyama, H.; Okamoto, Y.; Kumada, M.; Hotta, K.; Nishida, M.; Takahashi, M.; Nakamura, T.; Shimomura, I.; Muraguchi, M.; Ohmoto, Y.; Funahashi, T.; Matsuzawa, Y. Adipocyte-derived plasma protein adiponectinacts as a platelet-derived growth factor-BB-binding proteinand regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation, 2002, 105(24), 2893 -2898.
41. Yamauchi, T.; Kamon, J.; Ito, Y.; Tsuchida, A.; Yokomizo, T.; Kita, S.; Sugiyama, T.; Miyagishi, M.; Hara, K.; Tsunoda, M.; Murakami, K.; Ohteki, T.; Uchida, S.; Takekawa, S.; Waki, H.; Tsuno, N.H.; Shibata, Y.; Terauchi, Y.; Froguel, P.; Tobe, K.; Koyasu, S.; Taira, K.; Kitamura, T.; Shimizu, T.; Nagai, R.; Kadowaki, T.Cloning of adiponectin receptors that mediate antidiabetic metaboliceffects. Nature, 2003, 423(6941), 762-769.
42. Diez, J.J.; Iglesias, P. The role of the novel adipocyte-derived hormoneadiponectin in human disease. Eur. J. Endocrinol., 2003, 148(3), 293-300.
43. Hotta, K.; Funahashi, T.; Arita, Y.; Takahashi, M.; Matsuda, M.; Okamoto, Y.; Iwahashi, H.; Kuriyama, H.; Ouchi, N.; Maeda, K.; Nishida, M.; Kihara, S.; Sakai, N.; Nakajima, T.; Hasegawa, K.; Muraguchi, M.; Ohmoto, Y.; Nakamura, T.; Yamashita, S.; Hanafusa, T.; Matsuzawa, Y. Plasma concentrations of a novel, adiposespecificprotein, adiponectin, in type 2 diabetic patients. Arterioscler.Thromb. Vasc. Biol., 2000, 20(6), 1595-1599.
44. Yang, W.S.; Lee, W.J.; Funahashi, T.; Tanaka, S.; Matsuzawa, Y.; Chao, C.L.; Chen, C.L.; Tai, T.Y.; Chuang, L.M. Plasma adiponectinlevels in overweight and obese Asians. Obes. Res., 2002, 10(11), 1104-1110.
45. Takahashi, M.; Arita, Y.; Yamagata, K.; Matsukawa, Y.; Okutomi, K.; Horie, M.; Shimomura, I.; Hotta, K.; Kuriyama, H.; Kihara, S.; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Genomicstructure and mutations in adipose-specific gene, adiponectin.Int. J. Obes. Relat. Metab. Disord., 2000, 24(7), 861-868.
46. Kissebah, A.H.; Sonnenberg, G.E.; Myklebust, J.; Goldstein, M.; Broman, K.; James, R.G.; Marks, J.A.; Krakower, G.R.; Jacob, H.J.; Weber, J.; Martin, L.; Blangero, J.; Comuzzie, A.G. Quantitativetrait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc. Natl. Acad. Sci. USA, 2000, 97(26), 14478-14483.
47. Qi, L.; Doria, A.; Manson, J.E.; Meigs, J.B.; Hunter, D.; Mantzoros, C.S.; Hu, F.B. Adiponectin genetic variability, plasmaadiponectin, and cardiovascular risk in patients with type 2 diabetes.Diabetes, 2006, 55(5), 1512-1516.
48. Pischon, T.; Girman, C.J.; Rifai, N.; Hotamisligil, G.S.; Rimm, E.B. Association between dietary factors and plasma adiponectinconcentrations in men. Am. J. Clin. Nutr., 2005, 81(4), 780-786.
49. Qi, L.; Rimm, E.; Liu, S.; Rifai, N.; Hu, F.B. Dietary glycemicindex, glycemic load, cereal fiber, and plasma adiponectinconcentration in diabetic men. Diabetes Care, 2005, 28(5), 1022-1028.
50. Mantzoros, C.S.; Williams, C.J.; Manson, J.E.; Meigs, J.B.; Hu, F.B. Adherence to the Mediterranean dietary pattern is positivelyassociated with plasma adiponectin concentrations in diabeticwomen. Am. J. Clin. Nutr., 2006, 84(2), 328 -335.
51. Nishizawa, H.; Shimomura, I.; Kishida, K.; Maeda, N.; Kuriyama, H.; Nagaretani, H.; Matsuda, M.; Kondo, H.; Furuyama, N.; Kihara, S.; Nakamura, T.; Tochino, Y.; Funahashi, T.; Matsuzawa, Y.Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes, 2002, 51(9), 2734-2741.
52. Hoffstedt, J.; Arvidsson, E.; Sjolin, E.; Wahlen, K.; Arner, P. Adiposetissue adiponectin production and adiponectin serum concentrationin human obesity and insulin resistance. J. Clin. Endocrinol.Metab., 2004, 89(3), 1391-1396.
53. Gale, S.M.; Castracane, V.D.; Mantzoros, C.S. Energy homeostasis, obesity and eating disorders: recent advances in endocrinology.J. Nutr., 2004, 134(2), 295-298.
54. Garg, A. Acquired and inherited lipodystrophies. N. Engl. J. Med., 2004, 350(12), 1220 -1234.
55. Gavrila, A.; Chan, J.L.; Yiannakouris, N.; Kontogianni, M.; Miller, L.C.; Orlova, C.; Mantzoros, C.S. Serum adiponectin levels are inverselyassociated with overall and central fat distribution but arenot directly regulated by acute fasting or leptin administration inhumans: cross-sectional and interventional studies. J. Clin. Endocrinol.Metab., 2003, 88(10), 4823-4831.
56. Arita, Y.; Kihara, S.; Ouchi, N.; Takahashi, M.; Maeda, K.; Miyagawa, J.; Hotta, K.; Shimomura, I.; Nakamura, T.; Miyaoka, K.; Kuriyama, H.; Nishida, M.; Yamashita, S.; Okubo, K.; Matsubara, K.; Muraguchi, M.; Ohmoto, Y.; Funahashi, T.; Matsuzawa, Y.Paradoxical decrease of an adiposespecific protein, adiponectin, inobesity. Biochem. Biophys. Res. Commun., 1999, 257(1), 79-83.
57. Hotta, K.; Funahashi, T.; Arita, Y.; Takahashi, M.; Matsuda, M.; Okamoto, Y.; Iwahashi, H.; Kuriyama, H.; Ouchi, N.; Maeda, K.; Nishida, M.; Kihara, S.; Sakai, N.; Nakajima, T.; Hasegawa, K.; Muraguchi, M.; Ohmoto, Y.; Nakamura, T.; Yamashita, S.; Hanafusa, T.; Matsuzawa, Y. Plasma concentrations of a novel, adiposespecificprotein, adiponectin, in type 2 diabetic patients. Arterioscler.Thromb. Vasc. Biol., 2000, 20(6), 1595-1599.
58. Yang, W.S.; Lee, W.J.; Funahashi, T.; Tanaka, S.; Matsuzawa, Y.; Chao, C.L.; Chen, C.L.; Tai, T.Y.; Chuang, L.M. Weight reductionincreases plasma levels of an adipose-derived anti-inflammatoryprotein, adiponectin. J. Clin. Endocrinol. Metab., 2001, 86(8), 3815-3819.
59. Weyer, C.; Funahashi, T.; Tanaka, S.; Hotta, K.; Matsuzawa, Y.; Pratley, R.E.; Tataranni, P.A. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.J. Clin. Endocrinol. Metab., 2001, 86(5), 1930 -1935.
60. Stefan, N.; Vozarova, B.; Funahashi, T.; Matsuzawa, Y.; Weyer, C.; Lindsay, R.S.; Youngren, J.F.; Havel, P.J.; Pratley, R.E.; Bogardus, C.; Tataranni, P.A. Plasma adiponectin concentration isassociated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease inwhole-body insulin sensitivity in humans. Diabetes, 2002, 51(6), 1884-1888.
61. Tworoger, S.S.; Eliassen, A.H.; Kelesidis, T.; Colditz, G.A.; Willett, W.C.; Mantzoros, C.S.; Hankinson, S.E. Plasma adiponectinconcentrations and risk of incident breast cancer. J. Clin. Endocrinol.Metab., 2007, 92(4), 1510-1516.
62. Stefan, N.; Bunt, J.C.; Salbe, A.D.; Funahashi, T.; Matsuzawa, Y.; Tataranni, P.A. Plasma adiponectin concentrations in children: relationshipswith obesity and insulinemia. J. Clin. Endocrinol. Metab., 2002, 87(10), 4652-4656.
63. Yamamoto, Y.; Hirose, H.; Saito, I.; Tomita, M.; Taniyama, M.; Matsubara, K.; Okazaki, Y.; Ishii, T.; Nishikai, K.; Saruta, T. Correlationof the adipocytederived protein adiponectin with insulin resistanceindex and serum high-density lipoprotein-cholesterol, independentof body mass index, in the Japanese population. Clin.Sci. (Lond)., 2002, 103(2), 137-142.
64. Schulze, M.B.; Rimm, E.B.; Shai, I.; Rifai, N.; Hu, F.B. Relationshipbetween adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care, 2004, 27(7), 1680 -1687.
65. Mantzoros, C.; Petridou, E.; Dessypris, N.; Chavelas, C.; Dalamaga, M.; Alexe, D.M.; Papadiamantis, Y.; Markopoulos, C.; Spanos, E.; Chrousos, G.; Trichopoulos, D. Adiponectin and breastcancer risk. J. Clin. Endocrinol. Metab., 2004, 89(3), 1102-1117.
66. Miyoshi, Y.; Funahashi, T.; Kihara, S.; Taguchi, T.; Tamaki, Y.; Matsuzawa, Y.; Noguchi, S. Association of serum adiponectin levelswith breast cancer risk. Clin. Cancer Res., 2003, 9(15), 5699-5704.
67. Chen, D.C.; Chung, Y.F.; Yeh, Y.T.; Chaung, H.C.; Kuo, F.C.; Fu, O.Y.; Chen, H.Y.; Hou, M.F.; Yuan, S.S. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett., 2006, 237(1), 109 -114.
68. Petridou, T.E.; Mitsiades, N.; Gialamas, S.; Angelopoulos M.; Skalkidou, A.; Dessypris, N.; His, A.; Lazaris, N.; Polyzos, A.; Syrigos, C.; Brennan, M.A.; Tseleni-Balafouta, S.; Mantzoros, S.C.Circulating adiponectin levels and expression of adiponectin receptorsin relation to lung cancer: two case-control studies. Oncology, 2007, 73(3-4), 261-269.
69. Dal Maso, L.; Augustin, L.S.; Karalis, A.; Talamini, R.; Franceschi, S.; Trichopoulos, D.; Mantzoros, C.S.; La Vecchia, C.Circulating adiponectin and endometrial cancer risk. J. Clin. Endocrinol.Metab., 2004, 89(3), 1160 -1163.
70. Petridou, E.; Mantzoros, C.; Dessypris, N.; Koukoulomatis, P.; Addy, C.; Voulgaris, Z.; Chrousos, G.; Trichopoulos, D. Plasmaadiponectin concentrations in relation to endometrial cancer: acase-control study in Greece. J. Clin. Endocrinol. Metab., 2003, 88(3), 993-997.
71. Avcu, F.; Ural, A.U.; Yilmaz, M.I.; Bingol, N.; Nevruz, O.; Caglar, K. Association of plasma adiponectin concentrations with chroniclymphocytic leukemia and myeloproliferative diseases. Int. J.Hematol., 2006, 83(3), 254-258.
72. Cust, A.E.; Kaaks, R.; Friedenreich, C.; Bonnet, F.; Laville, M.; Lukanova, A.; Rinaldi, S.; Dossus, L.; Slimani, N.; Lundin, E.; Tjønneland, A.; Olsen, A.; Overvad, K.; Clavel-Chapelon, F.; Mesrine, S.; Joulin, V.; Linseisen, J.; Rohrmann, S.; Pischon, T.; Boeing, H.; Trichopoulos, D.; Trichopoulou, A.; Benetou, V.; Palli, D.; Berrino, F.; Tumino, R.; Sacerdote, C.; Mattiello, A.; Quirós, J.R.; Mendez, M.A.; Sánchez, M.J.; Larrañaga, N.; Tormo, M.J.;, Ardanaz, E.; Bueno-de-Mesquita, H.B.; Peeters, P.H.; van Gils, C.H.; Khaw, K.T.; Bingham, S.; Allen, N.; Key, T.; Jenab, M.; Riboli, E. Plasma adiponectin levels and endometrial cancer risk inpre- and postmenopausal women. J. Clin. Endocrinol. Metab., 2007, 92(1), 255-263.
73. Wei, E.K.; Giovannucci, E.; Fuchs, C.S.; Willett, W.C.; Mantzoros, C.S. Low plasma adiponectin levels and risk of colorectal cancer inmen: a prospective study. J. Natl. Cancer Inst., 2005, 97(22), 1688-1694.
74. Goktas, S.; Yilmaz, M.I.; Caglar, K.; Sonmez, A.; Kilic, S.; Bedir, S. Prostate cancer and adiponectin. Urology, 2005, 65(6), 1168-1172.
75. Michalakis, K.; Williams, C.J.; Mitsiades, N.; Blakeman, J.; Balafouta-Tselenis, S.; Giannopoulos, A.; Mantzoros, C.S. Serumadiponectin concentrations and tissue expression of adiponectin arereduced in patients with prostate cancer: a case-control study. CancerEpidemiol. Biomarkers Prev., 2007, 16(2), 308 -313.
76. Baillargeon, J.; Platz, E.A.; Rose, D.P.; Pollock, B.H.; Ankerst, D.P.; Haffner, S.; Higgins, B.; Lokshin, A.; Troyer, D.; Hernandez, J.; Lynch, S.; Leach, R.J.; Thompson, I.M. Obesity, adipokines, and prostate cancer in a prospective population-based study. CancerEpidemiol. Biomarkers Prev., 2006, 15(7), 1331-1335.
77. Ishikawa, M.; Kitayama, J.; Kazama, S.; Hiramatsu, T.; Hatano, K.; Nagawa, H. Plasma adiponectin and gastric cancer. Clin. CancerRes., 2005, 11(2 PT 1), 466-472.
78. Spyridopoulos, T.N.; Petridou, E.T.; Skalkidou, A.; Dessypris, N.; Chrousos, G.P.; Mantzoros, C.S. Low adiponectin levels are associatedwith renal cell carcinoma: a case-control study. Int. J. Cancer., 2007, 120(7), 1573-1578.
79. Petridou, E.; Mantzoros, C.S.; Dessypris, N.; Dikalioti, S.K.; Trichopoulos, D. Adiponectin in relation to childhood myeloblasticleukaemia. Br. J. Cancer, 2006, 94(1), 156-160.
80. Folkman, J. What is the evidence that tumors are angiogenesisdependent? J. Natl. Cancer Inst., 1990, 82(1), 4-6.
81. Bråkenhielm, E.; Veitonmäki, N.; Cao, R.; Kihara, S.; Matsuzawa, Y.; Zhivotovsky, B.; Funahashi, T.; Cao, Y. Adiponectin-inducedantiangiogenesis and antitumor activity involve caspase-mediatedendothelial cell apoptosis. Proc. Natl. Acad. Sci. USA, 2004, 101(8), 2476-2481.
82. Cao, R.; Wu, H.L.; Veitonmäki, N.; Linden, P.; Farnebo, J.; Shi, G.Y.; Cao, Y. Suppression of angiogenesis and tumor growth bythe inhibitor K1-5 generated by plasmin-mediated proteolysis.Proc. Natl. Acad. Sci. USA, 1999, 96(10), 5728 -5733.
83. Goldstein, B.J.; Scalia, R. Adiponectin: a novel adipokine linkingadipocytes and vascular function. J. Clin. Endocrinol. Metab., 2004, 89(6), 2563-2568.
84. Calle, E.E.; Rodriguez, C.; Walker-Thurmond, K.; Thun, M.J.Overweight, obesity, and mortality from cancer in a prospectivelystudied cohort of U.S. adults. N. Engl. J. Med., 2003, 348(17), 1625-1638.
85. Carroll, K.K. Obesity as a risk factor for certain types of cancer.Lipids, 1998, 33(11), 1055-1059.
86. Bergstrom, A.; Pisani, P.; Tenet, V.; Wolk, A.; Adami, H.O. Overweightas an avoidable cause of cancer in Europe. Int. J. Cancer, 2001, 91(3), 421-430.
87. Peto, J. Cancer epidemiology in the last century and the next decade.Nature, 2001, 411(6835), 390-395.
88. Cleary, M.P.; Maihle, N.J. The role of body mass index in therelative risk of developing premenopausal versus postmenopausalbreast cancer. Proc. Soc. Exp. Biol. Med., 1997, 216(1), 28-43.
89. Willett, W.C. Fat, energy and breast cancer. J. Nutr., 1997, 127(5Suppl), 921-3S.
90. Galanis, D.J.; Kolonel, L.N.; Lee, J.; Le Marchand, L. Anthropometricpredictors of breast cancer incidence and survival in amulti-ethnic cohort of female residents of Hawaii, United States.Cancer Causes Control, 1998, 9(2), 217-224.
91. Schoeller, D. A.; Cella, L. K.; Sinha, M. K.; Caro, J. F. Entrainmentof the diurnal rhythm of plasma leptin to meal timing. J. Clin.Invest., 1997, 100(7), 1882-1887.
92. Sinha, M. K.; Ohannesian, J. P.; Heiman, M. L.; Kriauciunas, A.; Stephens, T. W.; Magosin, S.; Marco, C.; Caro, J. F. Nocturnal riseof leptin in lean, obese, and non-insulin dependent diabetes mellitussubjects. J. Clin. Invest., 1996, 97(5), 1344-1347.
93. Ahima, R. S.; Prabakaran, D.; Mantzoros, C.; Qu, D.; Lowell, B.; Maratos-Flier, E.; Flier, J. S. Role of leptin in the neuroendocrineresponse to fasting. Nature, 1996, 382, (6588), 250-252.
94. Flier, J. S. Clinical review 94: What's in a name? In search of leptin's physiologic role. J. Clin. Endocrinol. Metab., 1998, 83(5), 1407-1413.
95. Boden, G.; Chen, X.; Mozzoli, M.; Ryan, I. Effect of fasting onserum leptin in normal human subjects. J. Clin. Endocrinol. Metab., 1996, 81(23), 3419-3423.
96. Frederich, R. C.; Lollmann, B.; Hamann, A.; Napolitano-Rosen, A.; Kahn, B. B.; Lowell, B. B.; Flier, J. S. Expression of ob mRNAand its encoded protein in rodents. Impact of nutrition and obesity.J Clin. Invest., 1995, 96(3), 1658-1663.
97. der Merwe, M. T.; Panz, V. R.; Crowther, N. J.; Schlaphoff, G. P.; Gray, I. P.; Froguel, P.; Joffe, B. I.; Lonnroth, P. N. Free fatty acidsand insulin levels-Relationship to leptin levels and body compositionin various patient groups from South Africa. J. Obes. Relat.Metab. Disord., 1999, 23(9), 909-917.
98. Thomas, T.; Burguera, B.; Melton, L. J. III.; Atkinson, E. J.; O'Fallon, W. M.; Riggs, B. L.; Khosla, S. Relationship of serumleptin levels with body composition and sex steroid and insulin levelsin men and women. Metabolism, 2000, 49(10), 1278-1284.
99. Blum, W. F.; Englaro, P.; Attanasio, A. M.; Kiess, W.; Rascher, W.Human and clinical perspectives on leptin. Proc. Nutr. Soc., 1998, 57(3), 477-485.
100. Kolaczynski, J. W.; Considine, R. V.; Ohannesian, J.; Marco, C.; Opentanova, I.; Nyce, M. R.; Myint, M.; Caro, J. F. Responses of leptin to short-term fasting and refeeding in humans: A link withketogenesis but not ketones themselves. Diabetes, 1996, 45(11), 1511-1515.
101. Kolaczynski, J. W.; Ohannesian, J. P.; Considine, R. V.; Marco, C.C.; Caro, J. F. Response of leptin to short-term and prolonged overfeedingin humans. J. Clin. Endocrinol. Metab., 1996, 81(11), 4162-4165.
102. Hamilton, B. S.; Paglia, D.; Kwan, A. Y.; Deitel, M. Increasedobese mRNA expression in omental fat cells from massively obesehumans. Nat. Med., 1995, 1(9), 953-956.
103. Korbonits, M.; Trainer, P. J.; Little, J. A.; Edwards, R.; Kopelman, P. G.; Besser, G. M.; Svec, F.; Grossman, A. B. Leptin levels donot change acutely with food administration in normal or obesesubjects, but are negatively correlated with pituitary-adrenal activity.Clin. Endocrinol. (Oxf.), 1997, 46(6), 751-757.
104. Kohn, E. C.; Liotta, L. A. Invasion and metastasis: New approachesto an old problem. Oncology (Huntingt.), 1993, 7(4), 47-52.
105. Rose, D. P.; Gilhooly, E. M.; Nixon, D. W. Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin (Review). Int. J. Oncol., 2002, 21(6), 1285-1292.
106. Rose, D. P. Effects of dietary fatty acids on breast and prostatecancers: Evidence from in vitro experiments and animal studies.Am. J. Clin. Nutr., 1997, 66(6 Suppl), 1513S-1522S.
107. Rose, D. P.; Connolly, J. M. Omega-3 fatty acids as cancer chemopreventiveagents. Pharmacol. Ther., 1999, 83(3), 217-244.
108. Rose, D. P.; Connolly, J. M. Dietary fat and breast cancer metastasisby human tumor xenografts. Breast Cancer Res. Treat., 1997, 46(2-3), 225-237.
109. Takahashi, Y.; Ide, T. Dietary n-3 fatty acids affect mRNA level of brown adipose tissue uncoupling protein 1, and white adipose tissueleptin and glucose transporter 4 in the rat. Br. J. Nutr., 2000, 84(2), 175-184.
110. Raclot, T.; Groscolas, R.; Langin, D.; Ferre, P. Site-specific regulationof gene expression by n-3 polyunsaturated fatty acids in ratwhite adipose tissues. J. Lipid Res., 1997, 38(10), 1963-1972.
111. Hun, C. S.; Hasegawa, K.; Kawabata, T.; Kato, M.; Shimokawa, T.; Kagawa, Y. Increased uncoupling protein2 mRNA in white adiposetissue, and decrease in leptin, visceralfat, blood glucose, and cholesterol in KK-Ay mice fed with eicosapentaenoic and docosahexaenoic acids in addition to linolenic acid. Biochem. Biophys.Res. Commun., 1999, 259(1), 85-90.
112. Wang, H.; Storlien, L. H.; Huang, X.F. Effects of dietary fat typeson body fatness, leptin, and ARC leptin receptor, NPY, and AgRPmRNA expression. Am. J. Physiol. Endocrinol. Metab., 2002, 282(6), E1352-9.
113. Park, H. Y.; Kwon, H. M.; Lim, H. J.; Hong, B. K.; Lee, J. Y.; Park, B. E.; Jang, Y.; Cho, S. Y.; Kim, H.S. Potential role of leptinin angiogenesis: Leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp.Mol. Med., 2001, 33(2), 95-102.
114. Oda, A.; Taniguchi, T.; Yokoyama, M. Leptin stimulates rat aorticsmooth muscle cell proliferation and migration. Kobe J. Med. Sci., 2001, 47(3), 141-150.
115. Hardwick, J. C.; Van Den Brink, G. R.; Offerhaus, G. J.; Van Deventer, S. J.; Peppelenbosch, M. P. Leptin is a growth factor forcolonic epithelial cells. Gastroenterology, 2001, 121(1), 79-90.
116. Liu, Z.; Uesaka, T.; Watanabe, H.; Kato, N. High fat diet enhancescolonic cell proliferation and carcinogenesis in rats by elevating serumleptin. Int. J. Oncol., 2001, 19(5), 1009-1014.
117. Dieudonne, M. N.; Machinal-Quelin, F.; Serazin-Leroy, V.; Leneveu, M. C.; Pecquery, R.; Giudicelli, Y. Leptin mediates aproliferative response in human MCF7 breast cancer cells. Biochem.Biophys. Res. Commun., 2002, 293(1), 622-628.
118. Liekens, S.; De Clercq, E.; Neyts, J. Angiogenesis: Regulators and clinical applications. Biochem. Pharmacol., 2001, 61(3), 253-270.
119. Smith, S. K. Regulation of angiogenesis in the endometrium.Trends Endocrinol. Metab., 2001, 12(4), 147-151.
120. Spranger, J.; Pfeiffer, A. F. New concepts in pathogenesis and treatment of diabetic retinopathy. Exp. Clin. Endocrinol. Diabetes, 2001, 109(Suppl. 2): S438-50.
121. Folkman, J. What is the evidence that tumors are angiogenesisdependent? J. Natl. Cancer Inst., 1990, 82(1), 4-6.
122. Sierra-Honigmann, M. R.; Nath, A. K.; Murakami, C.; Garcia-Cardena, G.; Papapetropoulos, A.; Sessa, W. C.; Madge, L. A.; Schechner, J. S.; Schwabb, M. B.; Polverini, P. J.; Flores-Riveros, J. R. Biological action of leptin as an angiogenic factor. Science, 1998, 281(5383), 1683-1686.
123. Bouloumie, A.; Drexler, H. C.; Lafontan, M.; Busse, R. Leptin, theproduct of Ob gene, promotes angiogenesis. Circ. Res., 1998, 83(10), 1059-1066.
124. Kume, K.; Satomura, K.; Nishisho, S.; Kitaoka, E.; Yamanouchi, K.; Tobiume, S.; Nagayama, M. Potential role of leptin in endochondralossification. J. Histochem. Cytochem., 2002, 50(2), 159-169.
125. Lagiou, P.; Signorello, L. B.; Trichopoulos, D.; Tzonou, A.; Trichopoulou, A.; Mantzoros, C. S. Leptin in relation to prostatecancer and benign prostatic hyperplasia. Int. J. Cancer, 1998, 76(1), 25-28.
126. Chang, S.; Hursting, S. D.; Contois, J. H.; Strom, S. S.; Yamamura, Y.; Babaian, R. J.; Troncoso, P.; Scardino, P. S.; Wheeler, T. M.; Amos, C. I.; Spitz, M. R. Leptin and prostate cancer. Prostate, 2001, 46(1), 62-67.
127. Stattin, P.; Soderberg, S.; Hallmans, G.; Bylund, A.; Kaaks, R.; Stenman, U. H.; Bergh, A.; Olsson, T. Leptin is associated with increasedprostate cancer risk: A nested case-referent study. J. Clin.Endocrinol. Metab., 2001, 86(3), 1341-1345.
128. Hsing, A. W.; Chua, S. Jr.; Gao, Y. T.; Gentzschein, E.; Chang, L.; Deng, J.; Stanczyk, F. Z. Prostate cancer risk and serum levels of insulin and leptin: A population-based study. J. Natl. Cancer Inst., 2001, 93(10), 783-789.
129. Chilliard, Y.; Bonnet, M.; Delavaud, C.; Faulconnier, Y.; Leroux, C.; Djiane, J.; Bocquier, F. Leptin in ruminants. Gene expression inadipose tissue and mammary gland, and regulation of plasma concentration.Domest. Anim. Endocrinol., 2001, 21(4), 271-295.
130. O'brien, S. N.; Welter, B. H.; Price, T. M. Presence of leptin inbreast cell lines and breast tumors. Biochem. Biophys. Res.Commun., 1999, 259(3), 695-698.
131. Magoffin, D. A.; Weitsman, S. R.; Aagarwal, S. K.; Jakimiuk, A. J.Leptin regulation of aromatase activity in adipose stromal cellsfrom regularly cycling women. Ginekol. Pol., 1999, 70(1), 1-7.
132. Goodwin, P. J.; Ennis, M.; Pritchard, K. I.; Trudeau, M. E.; Koo, J.; Madarnas, Y.; Hartwick, W.; Hoffman, B.; Hood, N. Fasting insulinand outcome in early-stage breast cancer: Results of a prospectivecohort study. J. Clin. Oncol., 2002, 20(1), 42-51.
133. Petridou, E.; Belechri, M.; Dessypris, N.; Koukoulomatis, P.; Diakomanolis, E.; Spanos, E.; Trichopoulos, D. Leptin and body massindex in relation to endometrial cancer risk. Ann. Nutr.Metab., 2002, 46(3-4), 147-151.
134. Lebrecht, A.; Ludwig, E.; Huber, A.; Klein, M.; Schneeberger, C.; Tempfer, C.; Koelbl, H.; Hefler, L. Serum vascular endothelialgrowth factor and serum leptin in patients with cervical cancer.Gynecol. Oncol., 2002, 85(1), 32-35.
135. Baile, C. A.; Della-Fera, M. A.; Martin, R. J. Regulation of metabolismand body fat mass by leptin. Annu. Rev. Nutr., 2000, 20, 105-127.
136. Bahceci, M.; Tuzcu, A.; Akkus, M.; Yaldiz, M.; Ozbay, A. The effect of high-fat diet on the development of obesity and serumleptin level in rats. Eat. Weight Disord., 1999, 4(3) 128-132.
137. Lin, X.; Chavez, M. R.; Bruch, R. C.; Kilroy, G. E.; Simmons, L.A.; Lin, L.; Braymer, H. D.; Bray, G. A.; York, D. A. The effectsof a high fat diet on leptin mRNA, serum leptin and the response toleptin are not altered in a rat strain susceptible to high fat dietinducedobesity. J. Nutr., 1998, 128(10), 1606-1613.
138. Alberts, D. S.; Einspahr, J.; Rees-McGee, S.; Ramanujam, P.; Buller, M. K.; Clark, L.; Ritenbaugh, C.; Atwood, J.; Pethigal, P.; Earnest, D. Effects of dietary wheat bran fiber on rectal epithelialcell proliferation in patients with resection for colorectal cancers. J.Natl. Cancer Inst., 1990, 82(15), 1280-1285.
139. Agus, M. S.; Swain, J. F.; Larson, C. L.; Eckert, E. A.; Ludwig, D.S. Dietary composition and physiologic adaptations to energy restriction.Am. J. Clin. Nutr., 2000, 71(4), 901-907.
140. Liew, C.; Schut, H. A.; Chin, S. F.; Pariza, M. W.; Dashwood, R.H. Protection of conjugated linoleic acids against 2-amino-3-methylimidazo[4, 5-f]quinoline-induced colon carcinogenesis inthe F344 rat: A study of inhibitory mechanisms. Carcinogenesis, 1995, 16(12), 3037-3043.
141. Rahman, S. M.; Wang, Y.; Yotsumoto, H.; Cha, J.; Han, S.; Inoue, S.; Yanagita, T. Effects of conjugated linoleic acid on serum leptinconcentration, body-fat accumulation, and beta-oxidation of fattyacid in OLETF rats. Nutrition, 2001, 17(5), 385-390.
142. Chu, N. F.; Stampfer, M. J.; Spiegelman, D.; Rifai, N.; Hotamisligil, G. S.; Rimm, E. B. Dietary and lifestyle factors in relation toplasma leptin concentrations among normal weight and overweightmen. Int. J. Obes. Relat. Metab. Disord., 2001, 25(1), 106-114.
143. Liu, Z.; Uesaka, T.; Watanabe, H.; Kato, N. High fat diet enhancescolonic cell proliferation and carcinogenesis in rats by elevating serumleptin. Int. J. Oncol., 2001, 19(5), 1009-1014.
144. Hardwick, J. C.; Van Den Brink, G. R.; Offerhaus, G. J.; Van Deventer, S. J.; Peppelenbosch, M. P. Leptin is a growth factor forcolonic epithelial cells. Gastroenterology, 2001, 121(1), 79-90.
145. Wang, Y., Kuropatwinski, K. K., White, D. W., Hawley, T. S., Hawley, R. G., Tartaglia, L. A., and Baumann, H. Leptin receptoraction in hepatic cells. J. Biol. Chem., 1997, 272(26), 16216-16223.
146. Arpaci, F.; Yilmaz, M. I.; Ozet, A.; Ayta, H.; Ozturk, B.; Komurcu, S.; Ozata, M. Low serum leptin level in colon cancer patients withoutsignificant weight loss. Tumori, 2002, 88(2), 147-149.
147. Tessitore, L.; Vyzyo, B. Novel Marker for Breast Cancer Progression.Second Balkan Congress of Oncology, Izmir-Turkey, 1998, 163-167.
148. Wallace, A. M.; Sattar, N.; McMillan, D. C. Effect of weight lossand the inflammatory response on leptin concentrations in gastrointestinalcancer patients. Clin. Cancer Res., 1998, 4(12), 2977-2979.
149. Inui, A. Cancer anorexia-cachexia syndrome: Are neuropeptidesthe key? Cancer Res., 1999, 59(18), 4493-4501.
150. Carlson, G. L.; Saeed, M.; Little, R. A.; Irving, M. H. Serum leptinconcentrations and their relation to metabolic abnormalities in humansepsis. Am. J. Physiol., 1999, 276(4 Pt 1), E658-62.
151. Arnalich, F.; Lopez, J.; Codoceo, R.; Jim, N. M.; Madero, R.; Montiel, C. Relationship of plasma leptin to plasma cytokines and humansurvival in sepsis and septic shock. J. Infect. Dis., 1999, 180(3), 908-911.
152. Papathanassoglou, E. D.; Moynihan, J. A.; Ackerman, M. H.; Mantzoros, C. S. Serum leptin levels are higher but are not independentlyassociated with severity or mortality in the multiple organdysfunction/systemic inflammatory response syndrome: Amatched case control and a longitudinal study. Clin. Endocrinol., 2001, 54(2), 225-233.
153. Moses, A. G.; Dowidar, N.; Holloway, B.; Waddell, I.; Fearon, K.C.; Ross, J. A. Leptin and its relation to weight loss, ob gene expressionand the acute-phase response in surgical patients. Br. J.Surg., 2001, 88(4), 588-593.
154. Takabatake, N.; Nakamura, H.; Abe, S.; Hino, T.; Saito, H.; Yuki, H.; Kato, S.; Tomoike, H. Circulating leptin in patients withchronic obstructive pulmonary disease. Am. J. Respir. Crit. CareMed., 1999, 159(4 Pt 1), 1215-1519.
155. Schols, A. M.; Creutzberg, E. C.; Buurman, W. A.; Campfield, L.A.; Saris, W. H.; Wouters, E. F. Plasma leptin is related to proinflammatorystatus and dietary intake in patients with chronic obstructivepulmonary disease. Am. J. Respir. Crit. Care Med., 1999, 160(4), 1220-1226.
156. Murdoch, D. R.; Rooney, E.; Dargie, H. J.; Shapiro, D.; Morton, J.J.; McMurray, J. J. Inappropriately low plasma leptin concentrationin the cachexia associated with chronic heart failure. Heart, 1999, 82(3), 352-356.
157. Filippatos, G. S.; Tsilias, K.; Venetsanou, K.; Karambinos, E.; Manolatos, D.; Kranidis, A.; Antonellis, J.; Kardaras, F.; Anthopoulos, L.; Baltopoulos, G. Leptin serum levels in cachecticheart failure patients. Relationship with tumor necrosis factor-alphasystem. Int. J. Cardiol., 2000, 76(2-3), 117-122.
158. Yarasheski, K. E.; Zachwieja, J. J.; Horgan, M. M.; Powderly, W.G.; Santiago, J. V.; Landt, M. Serum leptin concentrations in humanimmunodeficiency virus-infected men with low adiposity. Metabolism, 1997, 46(3), 303-305.
159. Ballinger, A.; Kelly, P.; Hallyburton, E.; Besser, R.; Farthing, M.Plasma leptin in chronic inflammatory bowel disease and HIV: Implicationsfor the pathogenesis of anorexia and weight loss. Clin.Sci. (Lond.), 1998, 94(5), 479-483.
160. Terzidis, A.; Sergentanis, N. T.; Antonopoulos, G.; Syrigos, C.; Efremidis, A.; Polyzos, A.; Dessypris, N.; Petridou T. E. ElevatedSerum Leptin Levels: A Risk Factor for Non-Small-Cell LungCancer? Oncology, 2009, 76(1), 19-25.
161. Oliveira, A. M.; Nascimento, A. G.; Lloyd, R. V. Leptin and leptinreceptor mRNA are widely expressed in tumors of adipocytic differentiation.Mod. Pathol., 2001, 14(6), 549-555.
162. Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K. Ghrelin is a growth-hormone-releasing acylated peptidefrom stomach. Nature, 1999, 402(6762), 656-660.
163. Bassil, A.K.; Häglund, V.; Brown, J.; Rudholm, T.; Hellström, P.M.; Näslund, E.; Lee, K.; Sanger, G.J. Little or no ability of obestatinto interact with ghrelin or modify motility in the rat gastrointestinaltract. Br. J. Pharmacol., 2007, 150(1), 58-64.
164. Nakazato, M.; Murakami, N.; Date, Y.; Kojima, M.; Matsuo, H.; Kangawa, K.; Matsukura, S. A role for ghrelin in the central regulationof feeding. Nature, 2001, 409(6817), 194-198.
165. Wren, A.M.; Seal, L.J.; Cohen, M.A.; Brynes, A.E.; Frost, G.S.; Murphy, K.G.; Dhillo, W.S.; Ghatei, M.A.; Bloom, S.R. Ghrelinenhances appetite and increases food intake in humans. J. Clin.Endocrinol. Metab., 2001, 86(12), 5992.
166. Cummings, D.E.; Purnell, J.Q.; Frayo, R.S.; Schmidova, K.; Wisse, B.E.; Weigle, D.S. A preprandial rise in plasma ghrelin levels suggestsa role in meal initiation in humans. Diabetes, 2001, 50(8), 1714-1719.
167. Cummings, D.E.; Weigle, D.S.; Frayo, R.S.; Breen, P.A.; Ma M.K.; Dellinger, E.P.; Purnell, J.Q. Plasma ghrelin levels after dietinducedweight loss or gastric bypass surgery. N. Engl. J. Med., 2002, 346(21), 1623-1630.
168. Yildiz, B.O.; Suchard, M.A.; Wong, M.L.; McCann, S.M.; Licinio, J. Alterations in the dynamics of circulating ghrelin adiponectin, and leptin in human obesity. Proc. Natl. Acad. Sci. USA, 2004, 101(28), 10434-10439.
169. Yoshihara, F.; Kojima, M.; Hosoda, H.; Nakazato, M.; Kangawa, K. Ghrelin: a novel peptide for growth hormone release and feedingregulation. Curr. Opin. Clin. Nutr. Metab. Care, 2002, 5(4), 391-395.
170. Tschöp, M.; Wawarta, R.; Riepl, RL.; Friedrich, S.; Bidlingmaier, M.; Landgraf, R.; Folwaczny, C. Post-pradial decrease of circulatinghuman ghrelin levels. J. Endocrinol. Invest., 2001, 24(6), RC19-RC21.
171. Muccioli, G.; Tschöp, M.; Papotii, M.; Deghenghi, R.; Heiman, M.; Ghingo, E. Neuroendocrine and peripheral activities of ghrelin: implicationin metabolism and obesity. Eur. J. Pharmacol., 2002, 440(2-3), 235-254.
172. Cummings, D.E.; Schwartz, M.W. Genetics and pathophysiologyof human obesity. Annu. Rev. Med., 2003, 54, 453-471.
173. Gormsen, L.C.; Gjedsted, J.; Gjedole, S.; Vestergaard, E.T.; Christiansen, J.S.; Jorgensen, J.O.; Nielsen, S.; Møller, N. Free forty acidsdecrease circulating ghrelin concentrations in humans. Eur. J.Endocrinol., 2006, 154(5), 667-673.
174. Arafat, M.A.; Otto, B.; Rochlitz, H.; Tschöp, M.; Bahr, V.; Mohlig, M.; Diederich, S.; Spranger, J.; Pfeiffer, A.F. Clucagon inhibitsghrelin secretion in humans. Eur. J. Endocrinol., 2005, 153(3), 397-402.
175. Arafat, A.M.; Perschel, F.H.; Otto, B.; Weickert, M.O.; Rochlitz, H.; Schofl, C.; Spranger, J.; Möhlig, M.; Pfeiffer, A.F. Glucagonsuppression of ghrelin secretion is exerted at hypothalamuspituitarylevel. J. Clin. Endocrinol. Metab., 2006, 91(9), 3528-3533.
176. Lopez, M.; Lage, R.; Saha, A.K.; Perez-Tilve, D.; Vazquez, M.J.; Varela, L.; Sangiao-Alvarellos, S.; Tovar, S.; Raghay, K.; Rodríguez-Cuenca, S.; Deoliveira, R.M.; Castañeda, T.; Datta, R.; Dong, J.Z.; Culler, M.; Sleeman, M.W.; Alvarez, C.V.; Gallego, R.; Lelliott, C.J.; Carling, D.; Tschöp, M.H.; Diéguez, C.; Vidal-Puig, A. Hypothalamic fatty acid metabolism mediates the orexigenic actionof ghrelin. Cell Metabol., 2008, 7(5), 389-399.
177. Dewys, W.D.; Begg, C.; Lavin, P.T.; Band, P.R.; Bennett, J.M.; Bertino, J.R.; Cohen, M.H.; Douglass, Jr. H.O.; Engstrom, P.F.; Ezdinli, E.Z.; Horton, J.; Johnson, G.J.; Moertel, C.G.; Oken, M.M.; Perlia, C.; Rosenbaum, C.; Silverstein, M.N.; Skeel, R.T.; Sponzo, R.W.; Tormey, D.C. Prognostic effect of weight loss priorto chemotherapy in cancer patients. Eastern Cooperative OncologyGroup. Am. J. Med., 1980, 69(4), 491-497.
178. Bruera, E. Pharmacological treatment of cachexia: any progress? Support Care. Cancer, 1998, 6(2), 109-113.
179. Shimizu, Y.; Nagaya, N.; Isobe, T.; Imazu, M.; Okumura, H.; Hosoda, H.; Kojima, M.; Kangawa, K.; Kohno, N. Increased plasmaghrelin level in lung cancer cachexia. Clin. Cancer Res., 2003, 9(2)774-778.
180. Garcia, J.M.; Garcia-Touza, M.; Hijazi, R.A.; Taffet, G.; Epner, D.; Mann, D.; Smith, R.G.; Cunningham, G.R.; Marcelli, M. Activeghrelin levels and active to total ghrelin ratio in cancer-inducedcachexia. J. Clin. Endocrinol. Metab., 2005, 90(5), 2920-2926.
181. Wolf, I.; Sadetzki, S.; Kanety, H.; Kundel, Y.; Pariente, C.; Epstein, N.; Oberman, B.; Catane, R.; Kaufman, B.; Shimon, I. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and coloncancer patients. Cancer, 2006, 106(4), 966-973.
182. Huang, Q.; Fan, Y.Z.; Ge, B.J.; Zhu, Q.; Tu, Z.Y. Circulating ghrelinin patients with gastric or colorectal cancer. Dig. Dis. Sci., 2007, 52(3), 803-809.
183. Hanada, T.; Toshinai, K.; Date, Y.; Kajimura, N.; Tsukada, T.; Hayashi, Y.; Kangawa, K.; Nakazato, M. Upregulation of ghrelinexpression in cachectic nude mice bearing human melanoma cells.Metabolism, 2004, 53(1), 84-88.
184. Liu, Y.L.; Malik, N.M.; Sanger, G.J.; Andrews, P.L. Ghrelin alleviatescancer chemotherapy-associated dyspepsia in rodents.Cancer Chemother. Pharmacol., 2006, 58(3), 326 -333.
185. Legakis, I.; Stathopoulos, J.; Matzouridis, T.; Stathopoulos, G.P.Decreased plasma ghrelin levels in patients with advanced cancerand weight loss in comparison to healthy individuals. AnticancerRes., 2009, 29(10), 3949-3952.